Lv42
458 积分 2024-08-26 加入
Overall Survival with Neoadjuvant Nivolumab in NSCLC
2小时前
求助中
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
2小时前
已完结
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004)_ a multicentre, singl
19天前
已完结
Tarlatamab Efficacy and Safety in Chinese Patients with Advanced Small Cell Lung Cancer: Phase 2 DeLLphi-307. P3.13.34, 2025 WCLC
1个月前
已关闭
Tarlatamab: First Approval
1个月前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
4个月前
已完结
Tarlatamab: First Approval
4个月前
已完结
T cell-engaging therapies - BiTEs and beyond
4个月前
已完结
The Lancet），详见：Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
4个月前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
